

17. Screening for Bladder Cancer

RECOMMENDATION

Routine screening for bladder cancer with urine dipstick, microscopic urinalysis, or urine cytology is not recommended in asymptomatic persons. All patients who smoke tobacco should be routinely counseled to quit smoking (see Chapter 54).

Burden of Suffering

Bladder cancer is an important cause of morbidity and mortality in the U.S., primarily in older men. Over 50,000 new cases and over 11,000 deaths due to bladder cancer are predicted to occur in 1995 in the U.S.¹ Risk rises steeply with age; over half of all deaths from bladder cancer occur after age 70. The incidence of bladder cancer is 3–4 times higher in men than women, and roughly twice as high in white men compared to black men.^{2,3} Among white men, the annual incidence of bladder cancer after age 65 is approximately 2/1,000 persons (vs. 0.1/1,000 under 65), and the lifetime probability of developing cancer is over 3%.³ The probability of dying from bladder cancer is much smaller, however—less than 1%. Cigarette smoking markedly increases the risk for bladder cancer (relative risk among smokers vs. nonsmokers = 1.5–7);^{4,5} nearly half of all new cases of bladder cancer occur in current or former smokers.² Occupational exposure to chemicals used in dye, leather, and tire and rubber industries has also been associated with increased risks of bladder cancer.⁴ Despite initial reports, positive associations between bladder cancer and consumption of coffee or artificial sweeteners have not been confirmed.^{2,6,7}

Accuracy of Screening Tests

Early asymptomatic bladder cancer may be associated with occult bleeding (microscopic hematuria) or the presence of dysplastic cells in the urine. The definition of significant hematuria varies, but more than 3–5 red blood cells (RBCs) per high-powered field in microscopic analysis of the urine sediment is usually considered abnormal.⁸ Urine dipsticks, which detect peroxidase activity of hemoglobin, provide a quick, inexpensive, and sensitive test for hematuria, and have largely supplanted microscopic urinalysis for screening in asymptomatic patients. Depending on the reference standard used (>2 or >5 RBCs per high-powered field on microscopy), dipstick urinalysis has a sensitivity of 91–100% and a specificity of 65–99% for de-

DR. RUPNATHJI (DR. RUPAK NATH)

testing microscopic hematuria.⁹⁻¹⁶ Dipsticks facilitate testing of serial urine specimens at home, which increases the detection of intermittent hematuria. False-positive dipstick results may be produced by myoglobin in the urine, and false-negative results may result from high concentrations of ascorbic acid, or from prolonged exposure of dipsticks to air.⁸

Urine cytology is more specific but less sensitive than microscopic hematuria as a screen for early bladder cancer. Because cytology is technically difficult and significantly more expensive than dipstick urinalysis, its use as an initial screening test has been limited to high-risk occupational screening programs. Specificity for cytology has been estimated to be as high as 95%,²⁴ and sequential screening combining urine dipstick and urine cytology may be able to reduce the false-positive rate of screening while maintaining sensitivity for clinically important cancers. Among men with dipstick hematuria in one screening study, urine cytology detected 10 of 17 patients with bladder cancer with a specificity of 96%, 6 of the 7 cases missed were well-differentiated, superficial lesions with a good prognosis.¹⁹ Rapid tests based on other tumor markers are under investigation.²⁵

Effectiveness of Early Detection

Survival in patients with bladder cancer is strongly associated with stage at diagnosis. Although most cancers are superficial at time of diagnosis, currently 10–20% of all cases of bladder cancer have invaded the muscular wall of the bladder when first diagnosed, with a much worse prognosis. Five-year survival for patients with superficial disease is over 90%, but falls to less than 50% with invasive disease.¹ The rationale for screening is that detecting and treating early asymptomatic bladder cancers may prevent progression to invasive disease or allow for more effective treatment of noninvasive tumors, which have a high rate of recurrence. Many cases detected on screening, however, are low-grade transitional cell cancers with low propensity for invasion; in contrast, since aggressive cancers may invade early, periodic screening may have a limited potential for detecting lethal bladder cancers at an early, treatable stage.²⁶

In the prospective screening studies cited above, all 26 cases of bladder cancer detected by screening were early tumors confined to superficial areas of the bladder (Stage T0 or T1).^{18,19} Compared to outcomes of cancers developing in the general population, cases detected by screening appeared to be less likely to progress over 3 years²⁷ or lead to death within 2 years.²⁸ Because of lead-time and length biases (see Chapter ii, Methodology), however, comparing case-survival is not sufficient to establish a benefit of screening, without information on rates of cancer and death in a comparable unscreened population. The incidence of invasive and fatal bladder cancer among screened men is very low, and it is also quite low in the general population of older men (<1/1,000 per year). Larger studies, with a comparable unscreened group and longer follow-up, are needed to determine whether screening improves the outcome of bladder cancer in high-risk populations. Despite early detection and treatment, 10 of 16 cancers detected by screening recurred within 3 years in one study.²⁷

Recommendations of Other Groups

No major organization recommends screening for bladder cancer in asymptomatic adults. The Canadian Task Force on the Periodic Health Examination recommends against routine screening in asymptomatic individuals and concludes that there is insufficient evidence for or against screening in specific high risk groups.²⁹ The American Cancer Society has not issued any specific guidelines on screening for bladder cancer.

Discussion

Dipstick and microscopic urinalysis are simple and sensitive tests for detecting hematuria from early tumors, but they are not sufficiently specific to be practical for screening for bladder cancer in the general population. Even among older high-risk populations, the predictive value of a positive screening test is low (5–8%). As a result, many persons without cancer will require diagnostic workups for false-positive test results and will be subjected to the costs, discomforts, and risks of cystoscopy and intravenous pyelography. More important, there is no proof that early detection significantly improves the prognosis for the small minority of patients found to have urologic malignancies. Most of the bladder cancers detected have a good prognosis in the absence of screening: 5-year survival for all bladder cancer is currently close to 80%.¹ Due to the frequent multifocal nature of bladder cancer, recurrences are common despite early detection and treatment. Conversely, the most lethal tumors become invasive early in the course of disease, and the potential to detect them at an earlier stage may be limited. Only a prospective study that includes an unscreened comparison group can determine whether screening is effective in reducing morbidity or mortality from bladder cancer (or other urologic cancers), and whether the benefits are sufficient to justify the costs and risks of screening and early treatment. In the absence of such evidence, routine screening cannot be recommended, due to the high rate of false-positive results, and the possibility of harm to asymptomatic patients, few of whom have cancer. Primary prevention may offer a safer and more effective strategy than screening for reducing mortality from urologic cancer, since smoking accounts for nearly half of all deaths from cancers of the bladder and kidney.²

CLINICAL INTERVENTION

Routine screening for bladder cancer with microscopic urinalysis, urine dipstick, or urine cytology is not recommended in asymptomatic persons (“D” recommendation). Persons working in high-risk professions (e.g., dye or rubber industries) may be eligible for screening at the worksite, although the benefit of this has not been determined. Men and women who smoke cigarettes should be advised that smoking significantly increases the

risk for bladder cancer, and all smokers should be routinely counseled to quit smoking (see Chapter 54).

The draft update for this chapter was prepared for the U.S. Preventive Services Task Force by David Atkins, MD, MPH, with contributions from materials prepared by Sarvesh Logsetty, MD, for the Canadian Task Force on the Periodic Health Examination.

REFERENCES

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. *CA Cancer J Clin* 1995;45:8–30.
2. National Cancer Institute. Cancer of the bladder. Bethesda: National Cancer Institute, 1990. (NIH Publication no. 90-722.)
3. Ries LAG, Miller BA, Hankey BF, et al. eds. SEER cancer statistics review 1973–1991: tables and graphs. Bethesda: National Cancer Institute, 1994. (NIH Publication no. 94-2789.)
4. Anton-Culver H, Lee-Felstein A, Taylor TH. Occupation and bladder cancer risk. *Am J Epidemiol* 1992;136:89–94.
5. Slattery ML, Schumacher MC, West DW, et al. Smoking and bladder cancer. The modifying effect of cigarettes on other factors. *Cancer* 1988;61:402–408.
6. Viscoli CM, Lachs MS, Horwitz RJ. Bladder cancer and coffee drinking: a summary of case-control research. *Lancet* 1993;341:1432–1437.
7. Chappel CI. A review and biological risk assessment of sodium saccharin. *Regul Toxicol Pharmacol* 1992;15:253–270.
8. Woolhandler S, Pels RJ, Bor DH, et al. Dipstick urinalysis screening of asymptomatic adults for urinary tract disorders: I. hematuria and proteinuria. *JAMA* 1989;262:1214–1219.
9. Loo SY, Scottolini AG, Luangphinit S, et al. Urine screening strategy employing dipstick analysis and selective culture: an evaluation. *Am J Clin Pathol* 1984;81:634–642.
10. Sewell DL, Burt SP, Gabbert NJ, et al. Evaluation of the Chemstrip 9 as a screening test for urinalysis and urine culture in men. *Am J Clin Pathol* 1985;83:740–743.
11. Mariani AJ, Luangphinit S, Loo S, et al. Dipstick chemical urinalysis: an accurate cost-effective screening test. *J Urol* 1984;132:64–66.
12. Hearne CR, Donnell MG, Fraser CC. Assessment of new urinalysis dipstick. *Clin Chem* 1980;26:170–171.
13. Shaw ST, Poon SY, Wong ET. Routine urinalysis: is the dipstick enough? *JAMA* 1985;253:1596–1600.
14. Szwed JJ, Schaust C. The importance of microscopic examination of the urinary sediment. *Am J Med Technol* 1982;48:141–143.
15. Smalley DL, Bryan JA. Comparative evaluation of biochemical and microscopic urinalysis. *Am J Med Technol* 1983;49:237–239.
16. Schumann GB, Greenberg NF. Usefulness of microscopic urinalysis as a screening procedure. *Am J Clin Pathol* 1979;71:452–456.
17. Muramaki S, Igarashi T, Hara S, Shimazaki J. Strategies for asymptomatic microscopic hematuria: a prospective study of 1,034 patients. *J Urol* 1990;144:99–101.
18. Messing EM, Young TB, Hunt VB, et al. Home screening for hematuria: results of a multi-clinic study. *J Urol* 1992;148:289–292.
19. Britton JP, Dowell AC, Whelan P, Harris CM. A community study of bladder cancer screening by the detection of occult urinary bleeding. *J Urol* 1992;148:788–790.
20. Messing EM, Young TB, Hunt VB, et al. The significance of asymptomatic microhematuria in men 50 or more years old: findings of a home screening study using urinary dipsticks. *J Urol* 1987;137:919–922.
21. Hiatt RA, Ordenez JD. Dipstick urinalysis screening, asymptomatic microhematuria, and subsequent urological cancers in a population-based sample. *Cancer Epidemiol Biomarkers Prev* 1994;3:1–5.
22. Mohr DN, Offord KP, Owen RA, et al. Asymptomatic microhematuria and urologic disease. *JAMA* 1986;256:224–229.
23. Mohr DN, Offord KP, Melton LJ. Isolated asymptomatic microhematuria: a cross sectional analysis of test-positive and test-negative patients. *J Gen Intern Med* 1987;2:318–324.
24. Farrow GM. Pathologist's role in bladder cancer. *Semin Oncol* 1979;6:198–206.
25. Attallah AM, Helmi H, El-Helali E, et al. A dipstick, dot-ELISA assay for the rapid detection of bladder cancer. *Cancer Detect Prev* 1991;15:495–499.

26. Farrow GM. Pathology of carcinoma in situ of the urinary bladder and related lesions. *J Cell Biochem* 1992;16(Suppl I):39-43.
27. Whelan P, Britton JP, Dowell AC. Three-year follow-up of bladder tumors found on screening. *Br J Urol* 1993;72:893-896.
28. Messing EM, Young TB, Hunt VB, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. *Urology* 1995;45:387-397.
29. Canadian Task Force on the Periodic Health Examination. Canadian guide to clinical preventive health care. Ottawa: Canada Communication Group, 1994:826-836.

DR. RUPNATHJI (DR. RUPAK NATH)